RJA
IHE icon

Raymond James & Associates’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Raymond James & Associates’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.34M Sell
47,257
-3,112
-6% -$217K ﹤0.01% 1906
2024
Q2 		$3.34M Sell
50,369
-2,969
-6% -$195K ﹤0.01% 1855
2024
Q1 		$3.62M Sell
53,338
-78,605
-60% -$5.2M ﹤0.01% 1800
2023
Q4 		$8.15M Sell
131,943
-38,979
-23% -$2.29M 0.01% 1232
2023
Q3 		$10.1M Sell
170,922
-630
-0.4% -$38.6K 0.01% 1028
2023
Q2 		$10.2M Sell
171,552
-19,752
-10% -$1.17M 0.01% 1038
2023
Q1 		$11.2M Buy
191,304
+73,008
+62% +$4.4M 0.01% 969
2022
Q4 		$7.34M Buy
118,296
+735
+0.6% +$44.2K 0.01% 1180
2022
Q3 		$6.64M Buy
117,561
+20,010
+21% +$1.23M 0.01% 1187
2022
Q2 		$6.23M Buy
97,551
+6,690
+7% +$425K 0.01% 1255
2022
Q1 		$5.88M Sell
90,861
-3,477
-4% -$220K 0.01% 1394
2021
Q4 		$6.28M Buy
94,338
+4,062
+4% +$258K 0.01% 1400
2021
Q3 		$5.51M Buy
90,276
+2,736
+3% +$174K 0.01% 1435
2021
Q2 		$5.42M Buy
87,540
+5,691
+7% +$346K ﹤0.01% 1441
2021
Q1 		$4.85M Buy
81,849
+7,587
+10% +$458K ﹤0.01% 1447
2020
Q4 		$4.44M Buy
74,262
+11,601
+19% +$661K ﹤0.01% 1406
2020
Q3 		$3.42M Sell
62,661
-17,430
-22% -$940K ﹤0.01% 1428
2020
Q2 		$4.11M Buy
80,091
+17,589
+28% +$884K 0.01% 1310
2020
Q1 		$2.8M Buy
62,502
+52,290
+512% +$2.64M ﹤0.01% 1385
2019
Q4 		$545K Sell
10,212
-23,469
-70% -$1.16M ﹤0.01% 2664
2019
Q3 		$1.57M Sell
33,681
-8,277
-20% -$396K ﹤0.01% 1912
2019
Q2 		$2.11M Buy
41,958
+1,260
+3% +$62.3K ﹤0.01% 1768
2019
Q1 		$2.09M Buy
40,698
+711
+2% +$35.4K ﹤0.01% 1741
2018
Q4 		$1.88M Sell
39,987
-16,464
-29% -$844K ﹤0.01% 1699
2018
Q3 		$3.16M Sell
56,451
-3,330
-6% -$182K ﹤0.01% 1519
2018
Q2 		$3.02M Sell
59,781
-13,104
-18% -$650K 0.01% 1499
2018
Q1 		$3.58M Buy
72,885
+8,166
+13% +$419K 0.01% 1336
2017
Q4 		$3.33M Buy
64,719
+4,128
+7% +$212K 0.01% 1365
2017
Q3 		$3.16M Sell
60,591
-4,425
-7% -$227K 0.01% 1330
2017
Q2 		$3.36M Buy
65,016
+2,397
+4% +$121K 0.01% 1243
2017
Q1 		$3.15M Buy
62,619
+11,136
+22% +$551K 0.01% 1258
2016
Q4 		$2.43M Buy
51,483
+4,089
+9% +$194K 0.01% 1372
2016
Q3 		$2.36M Sell
47,394
-2,979
-6% -$151K 0.01% 1358
2016
Q2 		$2.42M Sell
50,373
-3,192
-6% -$152K 0.01% 1225
2016
Q1 		$2.45M Sell
53,565
-36,588
-41% -$1.71M 0.01% 1171
2015
Q4 		$4.86M Buy
90,153
+2,874
+3% +$151K 0.02% 819
2015
Q3 		$4.31M Sell
87,279
-146,592
-63% -$8.4M 0.02% 820
2015
Q2 		$13.6M Buy
233,871
+102,222
+78% +$5.97M 0.05% 414
2015
Q1 		$7.57M Buy
131,649
+27,018
+26% +$1.48M 0.03% 561
2014
Q4 		$5.28M Sell
104,631
-56,559
-35% -$2.76M 0.03% 656
2014
Q3 		$7.54M Buy
161,190
+23,820
+17% +$1.08M 0.04% 450
2014
Q2 		$6.19M Buy
137,370
+31,011
+29% +$1.33M 0.04% 538
2014
Q1 		$4.49M Buy
106,359
+14,793
+16% +$620K 0.03% 622
2013
Q4 		$3.6M Buy
91,566
+8,505
+10% +$319K 0.03% 663
2013
Q3 		$2.94M Sell
83,061
-8,055
-9% -$284K 0.03% 693
2013
Q2 		$3.03M Buy
+91,116
New +$3.03M 0.03% 620

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RW
Rockport Wealth Fairview Park, Ohio $549M AUM 22.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Raymond James & Associates's IHE Position: Q3 2024 in Review

Raymond James & Associates reduced its iShares US Pharmaceuticals ETF (IHE) stake by 6.2% in Q3 2024, selling an estimated $217K and leaving 47,257 shares worth $3.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

Raymond James & Associates first reported a position in IHE in Q2 2013 and has held it in 46 quarters since. The position peaked at $13.6M in Q2 2015. 143 funds tracked by Wall St. Rank hold IHE as of Q3 2024.

  • Raymond James & Associates held 47,257 shares of iShares US Pharmaceuticals ETF worth $3.34M as of Q3 2024.
  • Raymond James & Associates sold 3,112 iShares US Pharmaceuticals ETF shares in Q3 2024, an estimated $217K.
  • iShares US Pharmaceuticals ETF made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1906 holding.
  • Raymond James & Associates first reported a position in iShares US Pharmaceuticals ETF in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's iShares US Pharmaceuticals ETF position peaked at $13.6M in Q2 2015.
  • 143 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.